Aldoxorubicin for the treatment of soft tissue sarcoma

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

(2016) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma

(2015) David A. Liebner   JOURNAL OF SURGICAL ONCOLOGY

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma

(2015) Sant P. Chawla et al.   JAMA Oncology

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma

(2014) Sant P. Chawla et al.   CANCER

Pharmacokinetic study of aldoxorubicin in patients with solid tumors

(2014) Monica M. Mita et al.   INVESTIGATIONAL NEW DRUGS

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Trends in survival for patients with metastatic soft-tissue sarcoma

(2010) Antoine Italiano et al.   CANCER